Literature DB >> 27225247

Elevated high-mobility group B1 levels in active adult-onset Still's disease associated with systemic score and skin rash.

Ju-Yang Jung1, Chang-Hee Suh1, Seonghyang Sohn2, Jin-Young Nam1, Hyoun-Ah Kim3.   

Abstract

High-mobility group box-1 (HMGB1) is a nuclear protein, and such prototypical damage-associated molecular patterns mediate the immune response in the noninfectious inflammatory response. Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder involved in the dysregulation of innate immunity. We investigated the serum HMGB1 level in patients with AOSD and evaluated its clinical significance. Blood samples were collected from 40 patients with active AOSD and 40 healthy controls (HC). Of the patients with AOSD, follow-up samples were collected from 16 patients after a resolution of AOSD disease activity. Serum HMGB1 levels in patients with AOSD were higher than those of the HC (10.0 ± 5.85 vs. 5.15 ± 1.79 ng/mL, p < 0.001). Serum HMGB1 levels were found to be correlated with C-reactive protein (CRP) and the systemic score. The AOSD patient who had a sore throat showed a higher serum HMGB1 level than those patients who did not, and the patient with a skin rash had higher levels than the patients without. In addition, the serum HMGB1 levels were decreased after the resolution of disease activity in the AOSD patients who were followed up. The serum HMGB1 levels were elevated in AOSD patients compared to the HC and were correlated with both CRP and the systemic score. The HMGB1 levels were associated with skin rash and a sore throat in AOSD patients. After the resolution of disease activity, serum HMGB1 levels were found to have decreased.

Entities:  

Keywords:  Adult-onset Still’s disease; Biomarker; Disease activity; High-mobility group box-1

Mesh:

Substances:

Year:  2016        PMID: 27225247     DOI: 10.1007/s10067-016-3314-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

Review 1.  The functions of HMGB1 depend on molecular localization and post-translational modifications.

Authors:  U Andersson; D J Antoine; K J Tracey
Journal:  J Intern Med       Date:  2014-11       Impact factor: 8.989

2.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine.

Authors:  Noboru Taniguchi; Ko-ichi Kawahara; Kazunori Yone; Teruto Hashiguchi; Munekazu Yamakuchi; Masamichi Goto; Keiichi Inoue; Shingo Yamada; Kosei Ijiri; Shunji Matsunaga; Toshihiro Nakajima; Setsuro Komiya; Ikuro Maruyama
Journal:  Arthritis Rheum       Date:  2003-04

Review 3.  Role of high mobility group box 1 in inflammatory disease: focus on sepsis.

Authors:  Jong-Sup Bae
Journal:  Arch Pharm Res       Date:  2012-10-09       Impact factor: 4.946

4.  High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE).

Authors:  D A Abdulahad; J Westra; E Reefman; E Zuidersma; J Bijzet; P C Limburg; C G M Kallenberg; M Bijl
Journal:  Lupus       Date:  2013-04-02       Impact factor: 2.911

5.  Adult Still's disease: manifestations, disease course, and outcome in 62 patients.

Authors:  J Pouchot; J S Sampalis; F Beaudet; S Carette; F Décary; M Salusinsky-Sternbach; R O Hill; A Gutkowski; M Harth; D Myhal
Journal:  Medicine (Baltimore)       Date:  1991-03       Impact factor: 1.889

6.  High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway.

Authors:  Hui-Fang Guo; Shu-Xia Liu; Yu-Jun Zhang; Qing-Juan Liu; Jun Hao; Li-Xia Gao
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

Review 7.  The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis.

Authors:  Yu Chen; Wei Sun; Rongfen Gao; Yuying Su; Hisanori Umehara; Lingli Dong; Feili Gong
Journal:  Rheumatology (Oxford)       Date:  2013-04-12       Impact factor: 7.580

8.  High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts.

Authors:  Heidi Wähämaa; Hanna Schierbeck; Hulda S Hreggvidsdottir; Karin Palmblad; Anne-Charlotte Aveberger; Ulf Andersson; Helena Erlandsson Harris
Journal:  Arthritis Res Ther       Date:  2011-08-26       Impact factor: 5.156

9.  The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.

Authors:  Dubravka Bobek; Danka Grčević; Nataša Kovačić; Ivan Krešimir Lukić; Marija Jelušić
Journal:  Pediatr Rheumatol Online J       Date:  2014-12-03       Impact factor: 3.054

10.  HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response.

Authors:  Mudan Lu; Shanshan Yu; Wei Xu; Bo Gao; Sidong Xiong
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

View more
  9 in total

Review 1.  Association of serum/plasma high mobility group box 1 with autoimmune diseases: A systematic review and meta-analysis.

Authors:  Bin Zhu; Qing Zhu; Nanfang Li; Ting Wu; Shasha Liu; Shanshan Liu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 2.  Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.

Authors:  Meng-Yan Wang; Jin-Chao Jia; Cheng-De Yang; Qiong-Yi Hu
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

Review 3.  Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.

Authors:  Ju-Yang Jung; Ji-Won Kim; Chang-Hee Suh; Hyoun-Ah Kim
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

4.  Serum sTREM-1 in adult-onset Still's disease: a novel biomarker of disease activity and a potential predictor of the chronic course.

Authors:  Zhihong Wang; Huihui Chi; Yue Sun; Jialin Teng; Tienan Feng; Honglei Liu; Xiaobing Cheng; Junna Ye; Hui Shi; Qiongyi Hu; Jinchao Jia; Tingting Liu; Liyan Wan; Zhuochao Zhou; Xin Qiao; Chengde Yang; Yutong Su
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

Review 5.  The Role of HMGB1 in Rheumatic Diseases.

Authors:  Yuanji Dong; Bingxia Ming; Lingli Dong
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

Review 6.  An Update on the Pathogenic Role of Neutrophils in Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.

Authors:  Ji-Won Kim; Mi-Hyun Ahn; Ju-Yang Jung; Chang-Hee Suh; Hyoun-Ah Kim
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

7.  Elevated expression of TLR2 and its correlation with disease activity and clinical manifestations in adult-onset Still's disease.

Authors:  Jae Ho Han; Mi-Hyun Ahn; Ju-Yang Jung; Ji-Won Kim; Chang-Hee Suh; Ji Eun Kwon; Hyunee Yim; Hyoun-Ah Kim
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

Review 8.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

Review 9.  Targeting Toll-like Receptor (TLR) Pathways in Inflammatory Arthritis: Two Better Than One?

Authors:  Sandra Santos-Sierra
Journal:  Biomolecules       Date:  2021-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.